CRBP Stock Summary and Trading Ideas (Corbus Pharmaceuticals Holdings | NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings trades on the NASDAQ stock market under the symbol CRBP.

As of February 13, 2026, CRBP stock price declined to $7.81 with 33,448 million shares trading.

CRBP has a beta of 1.58, meaning it tends to be more sensitive to market movements. CRBP has a correlation of 0.10 to the broad based SPY ETF.

CRBP has a market cap of $137.09 million. This is considered a Micro Cap stock.

In the last 3 years, CRBP traded as high as $61.90 and as low as $2.11.

The top ETF exchange traded funds that CRBP belongs to (by Net Assets): VTI, VXF, IWC, DFAS, AVSC.

CRBP has underperformed the market in the last year with a price return of -13.4% while the SPY ETF gained +14.6%. CRBP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.2% and -9.5%, respectively, while the SPY returned +0.4% and -1.4%, respectively.

CRBP support price is $7.45 and resistance is $8.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRBP shares will trade within this expected range on the day.